Skip to content

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million.

Back To Top